: 1642 Examiner: Gary B. Nickol

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

Applicant: Neil H. Bander

Serial No.: 09/357,709

Filed

: July 20, 1999

Title

: TREATMENT AND DIAGNOSIS OF PROSTATE CANCER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Copies of the references listed on the attached form PTO-1449 are enclosed.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804 Telephone: (617) 542-5070

Facsimile: (617) 542-8906

20663621.doc

Laurie Butler Lawrence

Reg. No. 46,593

RECEIVED TECH CENTER 1600/2900

06/04/2003 YCHADWIC 00000006 09357709

01 FC:1806

180.00 OP

CERTIFICATE OF DELIVERY BY HAND

I hereby certify that this correspondence is being delivered by hand on the date indicated below and is addressed to the U.S. Patent and Trademark Office, 2011 South Clark Place, Customer Window, Mail Stop IDS Crystal Plaza T wo, Lobby, Room 1B03, Arlington, VA 22202.

Date of Delivery

Signature

Typed or Printed Name of Person Signing Certificate

| Sheet | _1_ | of | _1_ |
|--------|-----|----|-----|
| DITOUT | | VΙ | |

| ostitute Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office | | Application No. RECEIVED | | |
|--|--|---|--|--|
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Neil H. Bander JUN 0 5 2003 | | |
| | | Group Art Unit | | |
| | | 1642 TECH CENTER 1600/2900 | | |
| | Patent and Trademark Office closure Statement oplicant | Patent and Trademark Office 10448-184003 closure Statement | | |

| U.S. Patent Documents | | | | | | | |
|-----------------------|--------------|--------------------|---------------------|----------|-------|----------|----------------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| | AA | | | | | | |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|--------|----------|-------------|---------------|-------|----------|-------|---------|
| Examiner | Desig. | Document | Publication | Country or | | - | Trans | slation |
| Initial | ID | Number | Date | Patent Office | Class | Subclass | Yes | No |
| | AB | | | | | | | |

| | Other D | ocuments (include Author, Title, Date, and Place of Publication) | | | |
|---------------------|--------------|---|--|--|--|
| Examiner Initial | Desig. ID | Document | | | |
| | AC | Chang et al., "Prostate-Specific Membrane Antigen: Much More Than a Prostrate Cancer Marker", Molecular Urology 3(3):313-321 (1999) | | | |
| | AD | Chang et al., "The clinical role of prostate-specific membrane antigen (PSMA)", <i>Urologic Oncology</i> 7:7-12 (2002) | | | |
| | AE | Chang et al., "Prostate-specific Membrane Antigen Is Produced in Tumor-associated Neovasculature", Clinical Cancer Research 674(5):2674-2681 (1999) | | | |
| | AF | Chang et al., "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature", Cancer Research 59:3192-3198 (1999) | | | |
| | AG | Chang et al., "Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma", <i>Urology</i> 57(6):1179-1183 (2001) | | | |
| | AH | Fracasso et al., "Anti-tumor Effects of Toxins Targeted to the Prostate Specific Membrane Antigen", The Prostate 53:9-23 (2002) | | | |
| | AI | Gong et al., "Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers", Cancer and Metastasis Reviews 18:483-490 (1999) | | | |
| | AJ | Gong et al., "Overview of Evolving Strategies Incorporating Prostate-Specific Membrane Antigen as Target for Therapy", <i>Molecular Urology</i> 4(3):217-223 (2000) | | | |
| | AK | Grauer et al., "Identification, Purification, and Subcellular Localization of Prostate-specific Membrane Antigen PSM' Protein in the LNCaP Prostatis Carcinoma Cell Line", Cancer Rearch 58:4787-4789 (1998) | | | |
| | AL | Liu et al., "Monoclonal Antibodies to the Extracellular Domain of Prostrate-specific Membrane Antigen Also React with Tumor Vascular Endothelium", Cancer Research 57:3629-3634 (1997) | | | |
| | AM | Smith-Jones et al., "In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostrate-specific Membrane Antigen", Cancer Research 60:5237-5243 (2000) | | | |
| | AN | Sokoloff et al., "A Dual-Monoclonal Sandwich Assay for Prostate-specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine", <i>The Prostate</i> 43:150-157 (2000) | | | |
| | AO | Wang et al., "Identification of Prostate Specific Membrane Antigen (PSMA) as the Target of Monoclonal Antibody 107-1A4 by Proteinchip®; Array, Surface-enhanced Laser Desorption/ionization (SELDI) Technology", Int. J. Cancer 92:871-876 (2001) | | | |

| Everying Cineshau | | | | |
|---|-----------------|--|--|--|
| Examiner Signature | Date Considered | | | |
| | | | | |
| | | | | |
| | | | | |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with | | | | |
| next communication to applicant | | | | |